Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort

Viet-Thi Tran, Raphaël Porcher, Isabelle Pane, Philippe Ravaud, Viet-Thi Tran, Raphaël Porcher, Isabelle Pane, Philippe Ravaud

Abstract

About 10% of people infected by severe acute respiratory syndrome coronavirus 2 experience post COVID-19 disease. We analysed data from 968 adult patients (5350 person-months) with a confirmed infection enroled in the ComPaRe long COVID cohort, a disease prevalent prospective e-cohort of such patients in France. Day-by-day prevalence of post COVID-19 symptoms was determined from patients' responses to the Long COVID Symptom Tool, a validated self-reported questionnaire assessing 53 symptoms. Among patients symptomatic after 2 months, 85% still reported symptoms one year after their symptom onset. Evolution of symptoms showed a decreasing prevalence over time for 27/53 symptoms (e.g., loss of taste/smell); a stable prevalence over time for 18/53 symptoms (e.g., dyspnoea), and an increasing prevalence over time for 8/53 symptoms (e.g., paraesthesia). The disease impact on patients' lives began increasing 6 months after onset. Our results are of importance to understand the natural history of post COVID-19 disease.

Conflict of interest statement

The authors declare no competing interests.

© 2022. The Author(s).

Figures

Fig. 1. Study flow chart.
Fig. 1. Study flow chart.
*The high number of patients without a confirmed infection is due to the limited availability of testing during the first wave of COVID-19 in March 2020, in France.
Fig. 2. Cumulative event curve for remission…
Fig. 2. Cumulative event curve for remission of post COVID-19 symptoms.
Time of remission was defined as the first time that patients reported no longer experiencing any symptoms of post COVID-19 disease. The time at risk started at entry in the cohort and ended on October 10, 2021. Follow-up data were censored at the participants’ latest observation point. Error bands represent 95% confidence intervals. Source data are provided as a Source Data file.
Fig. 3. Day-by-day trends in the prevalence…
Fig. 3. Day-by-day trends in the prevalence of post COVID-19 disease symptoms (A) and of their impact on patients’ lives (B).
A The figure presents the day-by-day prevalence of each of the 53 symptoms assessed by the Long COVID ST (grey lines). Examples of specific symptoms have been highlighted (coloured lines). For each symptom and at each observation point, we assumed that patients could either be “experiencing” or “not experiencing” the symptom. We assumed that their state at an arbitrary time was the same as the state at their previous observation point and that their states before their first observation and after their last observation are unknown. B The figure presents the day-by-day evolution of the six domains of patients’ lives that can be affected by post COVID-19 disease and are assessed by the Long COVID IT. For each item and at each observation point, we modelled patients answers as either “reporting” a significant impact of the disease on this domain” (i.e., item score >7) or “not reporting” this impact (i.e., item score <8). We assumed that their state at an arbitrary time was the same as the state at their previous observation point and that their states before their first observation and after their last observation are unknown. The red lines represent a similar model for the Patient Acceptable Symptomatic State (PASS) of the long COVID IT, which is the long COVID IT score below which 75% of patients find that their disease state is acceptable. Source data are provided as a Source Data file.

References

    1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard, Vol. 2020 (World Health organization, 2020).
    1. Augustin M, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Regional Health Eur. 2021;6:100122. doi: 10.1016/j.lanepe.2021.100122.
    1. Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603–605. doi: 10.1001/jama.2020.12603.
    1. Huang C, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220–232. doi: 10.1016/S0140-6736(20)32656-8.
    1. Nehme M, et al. COVID-19 symptoms: longitudinal evolution and persistence in outpatient settings. Ann. Intern. Med. 2020;174:723–725. doi: 10.7326/M20-5926.
    1. Ayoubkhani D, et al. Post-covid syndrome in individuals admitted to hospital with COVID-19: retrospective cohort study. BMJ. 2021;372:n693. doi: 10.1136/bmj.n693.
    1. Nehme M, Braillard O, Chappuis F, Courvoisier DS, Guessous I. Prevalence of symptoms more than seven months after diagnosis of symptomatic COVID-19 in an outpatient setting. Ann. Intern. Med. 2021;174:1252–1260. doi: 10.7326/M21-0878.
    1. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416–427. doi: 10.1016/S2215-0366(21)00084-5.
    1. Blomberg B, et al. Long COVID in a prospective cohort of home-isolated patients. Nat. Med. 2021;27:1607–1613. doi: 10.1038/s41591-021-01433-3.
    1. Taquet M, et al. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18:e1003773. doi: 10.1371/journal.pmed.1003773.
    1. Fang X, et al. Post-sequelae one year after hospital discharge among older COVID-19 patients: a multi-center prospective cohort study. J. Infect. 2022;84:179–186. doi: 10.1016/j.jinf.2021.12.005.
    1. Seeßle, J. et al. Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. Clin. Infect. Dis. ciab611 10.1093/cid/ciab611 (2021).
    1. Davis HE, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.
    1. Michelen, M. et al. Characterising long COVID: a living systematic review. BMJ Glob. Health6, e005427 (2021).
    1. Tran VT, Ravaud P. COllaborative open platform E-cohorts for research acceleration in trials and epidemiology. J. Clin. Epidemiol. 2020;124:139–148. doi: 10.1016/j.jclinepi.2020.04.021.
    1. Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 2 September 2021 (London, UK, 2021).
    1. Institut National de la Statistique et des etudes économiques. La macro SAS CALMAR. in Modèles, méthodes et outils statistiques, Vol. 2019 (Institut National de la Statistique et des etudes économiques, 2018).
    1. Tran VT, et al. Development and validation of the long covid symptom and impact tools, a set of patient-reported instruments constructed from patients’ lived experience. Clin. Infect. Dis. 2021;74:278–287. doi: 10.1093/cid/ciab352.
    1. NICE. COVID-19 Rapid Guideline: Managing the Long-term Effects of COVID-19 (NICE, 2020).
    1. Miyazato, Y. et al. Prolonged and late-onset symptoms of coronavirus disease 2019. Open Forum Infect. Dis.7, ofaa507 (2020).
    1. Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601–615. doi: 10.1038/s41591-021-01283-z.
    1. Takahashi T, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588:315–320. doi: 10.1038/s41586-020-2700-3.
    1. Christiansen DM, Berke ET. Gender- and sex-based contributors to sex differences in PTSD. Curr. Psychiatry Rep. 2020;22:19. doi: 10.1007/s11920-020-1140-y.
    1. Bury M. Chronic illness as biographical disruption. Sociol. Health Illn. 1982;4:167–182. doi: 10.1111/1467-9566.ep11339939.
    1. van Gelder MM, Bretveld RW, Roeleveld N. Web-based questionnaires: the future in epidemiology? Am. J. Epidemiol. 2010;172:1292–1298. doi: 10.1093/aje/kwq291.
    1. Huang L, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398:747–758. doi: 10.1016/S0140-6736(21)01755-4.
    1. Soriano, J. B., Murthy, S., Marshall, J. C., Relan, P. & Diaz, J. V. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis.22, e102–e107 (2021).
    1. Denscombe, M. (ed.) The Good Research Guide (Open University Press, 1997).
    1. World Health Organization. Global COVID-19 Clinical Platform Case Report Form (CRF) for Post COVID condition (Post COVID-19 CRF) (World Health Organization, 2021).
    1. Jackson C. Multi-state models for panel data: the msm Package for R. J. Stat. Softw. 2011;38:1–28. doi: 10.18637/jss.v038.i08.

Source: PubMed

3
Iratkozz fel